Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
108
Recruiting, any sponsor type, condition "chronic myeloid leukemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting108
- Completed881
108 trials
Showing 1 to 25, recently updated first.
Abhay Singh, MD MPHAcademic, hospital or other
NCT06630221 · 25 participants (planned) · Start Jun 17, 2025 · Primary completion Jan 1, 2028
Drug: Eltrombopag (EPAG) · For: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
Sites: Cleveland, Ohio
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruiting
Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
NCT07763054 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 31, 2026
Drug: Liposomal Amphotericin B · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 6 more
Sites: Hainan, China
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07269470 · 40 participants (planned) · Start Jul 13, 2026 · Primary completion Nov 1, 2029
Drug: Dasatinib; Ropeginterferon alfa-2b (P1101) · For: Chronic Myeloid Leukemia
Sites: Houston, Texas
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
Enliven TherapeuticsIndustry
NCT05304377 · 250 participants (planned) · Start May 22, 2022 · Primary completion Dec 2027
Drug: ELVN-001 · For: Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml
Sites: New York, New York; The Bronx, New York; Portland, Oregon · 45 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06928662 · 36 participants (planned) · Start Sep 23, 2025 · Primary completion Mar 9, 2028
Drug: Decitabine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Acute Undifferentiated Leukemia; Mixed Phenotype Acute Leukemia and 11 more
Sites: Seattle, Washington
- A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsPivotal-lookingRecruiting
Enliven TherapeuticsIndustry
NCT07905183 · 450 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2028
Drug: ELVN-001; TKI · For: Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Chronic Phase Chronic Myeloid Leukemia, BCR::ABL1 Positive CML
Sites: Atlanta, Georgia; Indianapolis, Indiana; Morristown, New Jersey · 4 sites in all
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
University of Wisconsin, MadisonAcademic, hospital or other
NCT07758218 · 22 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: agenT-797 · For: Allogenic Stem Cell Transplantation; Myeloid Malignancies; Lymphoid Malignancies and 3 more
Sites: Madison, Wisconsin
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02115295 · 508 participants (planned) · Start May 19, 2014 · Primary completion May 31, 2030
Drug: Cladribine; Cytarabine and 4 more · For: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 11 more
Sites: Houston, Texas
Thomas Ernst, Prof. Dr. med.Academic, hospital or other
NCT07789574 · 50 participants (planned) · Start Nov 2026 · Primary completion Jun 30, 2030
Drug: asciminib 200 mg BID · For: Chronic Myeloid Leukemia (CML)
Sites: Aachen, Germany; Berlin, Germany; Chemnitz, Germany · 10 sites in all
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07354074 · 50 participants (planned) · Start Apr 28, 2026 · Primary completion Feb 23, 2033
Drug: Asciminib single agent · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Sites: Chicago, Illinois; New Brunswick, New Jersey; New York, New York · 39 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03263572 · 90 participants (planned) · Start Nov 29, 2017 · Primary completion Nov 30, 2027
Drug: Blinatumomab; Cytarabine and 2 more · For: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression and 5 more
Sites: Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03589729 · 100 participants (planned) · Start Sep 19, 2018 · Primary completion Dec 31, 2027
Drug: Cladribine; Cytarabine and 3 more · For: Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells and 4 more
Sites: Houston, Texas
- Asciminib Roll-over StudyRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04877522 · 347 participants (planned) · Start Aug 30, 2022 · Primary completion Aug 30, 2030
Drug: Asciminib single agent; Imatinib and 4 more · For: Chronic Myelogenous Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Sites: Ann Arbor, Michigan; St Louis, Missouri; New York, New York · 88 sites in all
Uma BorateAcademic, hospital or other
NCT06523556 · 49 participants (planned) · Start Aug 2, 2024 · Primary completion Oct 31, 2027
Drug: Axatilimab; Azacitidine · For: Atypical Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm and 5 more
Sites: Columbus, Ohio; Portland, Oregon
- Vididencel in CML-CP Patients With MRDRecruiting
MendusIndustry
NCT07651878 · 24 participants (planned) · Start Apr 14, 2026 · Primary completion Sep 1, 2029
Drug: vididencel · For: CML (Chronic Myelogenous Leukemia)
Sites: Bergen, Norway
Mabwell (Shanghai) Bioscience Co., Ltd.Industry
NCT07914556 · 122 participants (planned) · Start Sep 16, 2026 · Primary completion Dec 2029
Drug: 6MW5311 · For: AML; Multiple Myeloma; CMML
Sites: Shanghai, China
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06236724 · 150 participants (planned) · Start Jan 31, 2024 · Primary completion Jul 1, 2033
Drug: Asciminib · For: Chronic Myeloid Leukemia
Sites: Houston, Texas
- Personalized NK Cell Therapy in CBTRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02727803 · 100 participants (planned) · Start May 19, 2016 · Primary completion May 31, 2027
Drug: Allogeneic Natural Killer Cell Line NK-92; Anti-Thymocyte Globulin and 6 more · For: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia and 23 more
Sites: Houston, Texas
National Cancer Institute (NCI)NIH
NCT06904066 · 86 participants (planned) · Start Oct 28, 2026 · Primary completion Apr 30, 2029
Drug: aldesleukin; cyclophosphamide and 2 more · For: Malignancy, Hematologic; Neoplasms, Hematologic; Neoplasms, Hematopoietic and 8 more
Sites: Bethesda, Maryland
- Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06629584 · 40 participants (planned) · Start Feb 14, 2025 · Primary completion Dec 31, 2026
Drug: Asciminib · For: Malignant Solid Tumors
Sites: Houston, Texas
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)Recruiting
University of FloridaAcademic, hospital or other
NCT05322850 · 40 participants (planned) · Start Aug 16, 2022 · Primary completion Sep 2027
Drug: Orca-Q · For: Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Mixed Phenotype Acute Leukemia and 4 more
Sites: Gainesville, Florida; Miami, Florida; St. Petersburg, Florida · 4 sites in all
- Prophylactic DLI-X for Leukemia Relapse After HCTPivotal-lookingRecruiting
University of ArizonaAcademic, hospital or other
NCT07254793 · 180 participants (planned) · Start Oct 26, 2026 · Primary completion Jun 1, 2030
Drug: Exercise Mobilized Prophylactic DLI; Standard Prophylactic DLI · For: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Acute Undifferentiated Leukemia (AUL) and 3 more
Sites: Tucson, Arizona
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT06013423 · 54 participants (planned) · Start Jul 23, 2024 · Primary completion Oct 31, 2031
Drug: Cyclophosphamide; Cyclosporine and 3 more · For: Acute Leukemia of Ambiguous Lineage; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 7 more
Sites: Seattle, Washington
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.